Key result
Quantitative CMR and molecular diagnostics improve noninvasive myocarditis evaluation to guide etiology-directed therapy.
Why the study?
Myocarditis remains a persistent clinical challenge due to its heterogeneous nature and nonspecific presentation, alongside rapidly evolving multimodal diagnostic and etiology-directed management strategies over the past five years.
This review highlights the shift in myocarditis care toward noninvasive multimodal diagnosis anchored by quantitative cardiac magnetic resonance and etiology-directed immunomodulatory management, while underscoring the urgent need for randomized clinical trials.
Answers are grounded in this paper and cite their sources.
Supports quantitative CMR-guided myocarditis evaluation; leaves open RCTs confirming etiology-directed immunomodulatory outcomes.
Myocarditis is an inflammatory disease of the myocardium caused by infectious, autoimmune, or toxic triggers; meanwhile, myocarditis remains a persistent clinical challenge due to the heterogeneous nature and often nonspecific presentation of myocarditis. Recent advances in cardiac magnetic resonance (CMR), particularly quantitative tissue characterization techniques, together with improvements in molecular diagnostic methods, have substantially strengthened the accuracy of noninvasive diagnosis. Concurrently, management strategies are increasingly shifting toward etiology-directed approaches, including targeted immunomodulatory therapies combined with optimized supportive care, thereby contributing to improved clinical outcomes. This review summarizes key developments in myocarditis over the past five years, with a focus on progress in multimodal diagnostic evaluation and precision management. We first outline current perspectives on etiology and clinical phenotypes, then examine the complementary roles of quantitative CMR imaging and endomyocardial biopsy in diagnostic decision-making. Recent advances in the management of major clinical subtypes, including viral myocarditis, immune checkpoint inhibitor-associated myocarditis, giant cell myocarditis, and pediatric myocarditis, are then discussed. Indeed, by integrating emerging clinical evidence, we highlight the evolving diagnostic and therapeutic framework, identify remaining challenges, and propose future directions to improve risk stratification and individualized patient care.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2026) conducted a review in Myocarditis. Multimodal diagnostic evaluation (including quantitative CMR and molecular biomarkers) and etiology-directed management was evaluated. Quantitative cardiac magnetic resonance imaging and molecular diagnostics improve noninvasive myocarditis evaluation, guiding etiology-directed immunomodulatory and supportive therapies.
Synapse has enriched 10 related papers. Consider them for comparative context: